Table 1 Patients baseline characteristic
From: Impact of splenectomy on prognosis in lymphoma with splenic involvement
Characteristic | All (n = 113) | DLBCL (n = 74) | Non-DLBCL (n = 39) | P value |
|---|---|---|---|---|
Age, years, n (%) | ||||
 Median (range) | 59 (18–82) | 61 (25–82) | 55 (18–74) |  |
  ≥ 60 | 52 (46.01) | 42 (56.75) | 13 (33.33) | 0.018* |
  < 60 | 61 (53.98) | 34 (45.95) | 26 (66.67) |  |
Male/female, n (ratio) | 59/54,1.09 | 39/35,1.11 | 20/19,1.05 | 0.886 |
Laboratory tests, median (IQR) | ||||
 WBC, × 109/L | 4.60 (3.00–7.25) | 4.80 (3.68–6.97) | 3.35 (2.40–7.70) | 0.519 |
 N, × 109/L | 2.70 (1.80–4.10) | 3.13 (2.15–4.20) | 2.00 (1.20–3.20) | 0.141 |
 L, × 109/L | 1.01 (0.71–1.65) | 1.08 (0.69–1.52) | 0.98 (0.78–2.30) | 0.517 |
 Platelets, × 109/L | 116.00 (73.50–187.00) | 124.00 (81.75–216.25) | 87.00 (67.00–150.00) | 0.458 |
 LDH, U/L | 303.00 (208.00–683.00) | 338.00 (214.25–684.50) | 238.00 (198.00–569.00) | 0.477 |
 ALT | 16.00 (11.00–27.00) | 16.50 (12.00–26.25) | 15.00 (10.00–35.00) | 0.355 |
 Cr, | 64.00 (55.00–79.5) | 63.50 (54.75–78.00) | 69.00 (55.00–89.00) | 0.624 |
 Ferritin | 376.9 (154.6–1071.7) | 632.49 (254.60–1202.90) | 177.50 (71.84–464.39) | 0.455 |
 APTT | 29.5 (26.75–34.60) | 29.65 (26.70–34.73) | 29.40 (26.90–34.70) | 0.468 |
 PT | 12.20 (11.40–13.15) | 12.15 (11.40–13.30) | 12.20 (11.10–13.00) | 0.255 |
 Ki-67 | 70.00 (40.00–80.00) | 80.00 (70.00–80.00) | 27.50 (10.00–57.50) |  < 0.001*** |
Laboratory tests, mean ± SD | ||||
 HB, g/L | 106.96 ± 27.80 | 105.51 ± 28.76 | 107 ± 26.00 | 0.268 |
 Albumin, g/L | 37.46 ± 7.63 | 36.48 ± 7.93 | 41.50 ± 6.71 | 0.262 |
 Globulin, g/L | 25.45 ± 6.46 | 25.69 ± 6.19 | 22.90 ± 7.00 | 0.556 |
 Fibrinogen | 3.78 ± 4.93 | 3.70 ± 1.11 | 2.54 ± 8.32 | 0.342 |
 Thickness of spleen, cm, median (IQR) | 5.70 (4.57–6.83) | 5.40 (4.50–6.50) | 6.60 (5.10–8.10) | 0.337 |
 HLH, n (%) | 10 (8.85) | 7 (9.45) | 3 (7.69) | 0.753 |
 Bone marrow involvement, n (%) | 54 (47.79) | 29 (39.19) | 25 (64.10) | 0.028 |
 B syndrome, n (%) | 54 (47.79) | 34 (45.95) | 20 (51.28) | 0.589 |
Ann Arbor stage, n (%) | ||||
 IS | 1 (0.88) | 1 (1.35) | 0 |  |
 II | 1 (0.88) | 0 | 1 (2.56) |  |
 III | 24 (21.24) | 15 (20.27) | 9 (23.08) |  |
 IV | 87 (76.99) | 58 (78.38) | 29 (74.36) | 0.462 |
Pathological classification, n (%) | ||||
 SMZL, | 18 (15.93) |  |  |  |
 DLBCL | 74 (65.49) |  |  |  |
 T/NK cell lymphoma* | 10 (8.85) |  |  |  |
FL | 4 (3.54) | Â | Â | Â |
MCL | 4 (3.54) | Â | Â | Â |
Others# | 3 (2.65) | Â | Â | Â |
SUV, median, (IQR) | 7.75 (4.51–16.65) | 12.00 (5.42–22.45) | 5.07 (3.55–6.38) | 0.400 |
Treatments, n (%) | ||||
Splenectomy | 12 (10.62) | 3 (4.05) | 9 (23.08) | Â |
Splenectomy followed by chemotherapy | 59 (52.21) | 44 (59.46) | 16 (41.02) | Â |
Treatments, n (%) | ||||
 Chemotherapy | 42 (37.17) | 27 (36.49) | 14(35.90) | 0.006** |
CD3 | 101 (89.3%) | 67 (90.5%) | 34 (87.2%) | 0.54 |
CD5 | 30 (26.5%) | 20 (27.05) | 19 (48.7%) | 0.53 |
CD19 | 25 (22.1%) | 11 (14.9%) | 5 (12.8%) | 0.87 |
CD20 | 101 (89.3%) | 68 (91.9%) | 34 (87.2%) | 0.93 |
CD22 | 6 (5.3%) | 2 (2.7%) | 0 | 0 < 0.001*** |